CD146‐mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR‐TKI resistance in lung cancer

CD146号 癌症研究 转移 癌症干细胞 吉非替尼 埃罗替尼 医学 表型 肺癌 癌细胞 干细胞 癌症 生物 病理 表皮生长因子受体 内科学 细胞生物学 基因 生物化学 川地34
作者
Fan Zhang,Jia Wang,Xiaobo Wang,Nan Wei,Haiyang Liu,Xiaoju Zhang
出处
期刊:Clinical Respiratory Journal [Wiley]
卷期号:13 (1): 23-33 被引量:22
标识
DOI:10.1111/crj.12976
摘要

Tumours are more likely to metastasize after the development of resistance to EGFR-TKIs. CD146 is a multifunctional molecule and is implicated in tumour invasion and metastasis; however, its role in lung cancer has not been clearly established.Here, we aimed to explore the relationship between CD146 pathway and stem cell phenotype after EGFR-TKI resistance in lung cancer.EGFR-TKI-resistant cell lines were established by exposing parental cells to erlotinib/gefitinib. The CD146 level was measured by a western blot, RT-PCR and immunocytochemistry fluorescent. Cell migration was examined by the transwell assay and the scratch assay. Stemness phenotype genes were evaluated by RT-PCR and stem cell phenotype was observed by the microsphere formation assay.CD146 and stemness phenotype genes increased while β-catenin decreased in acquired EGFR-TKI-resistant cell lines. CD146's over-expression induced the up-regulation of stemness-related genes and was inversely correlated with the β-catenin expression, which further increased the migration capability of resistant cancer cells. CD146's knockdown suppressed cell migration and stemness phenotype.CD146 molecule contributes to the stemness phenotype and migration in EGFR-TKI-resistant cells. CD146 might be a potential therapeutic target for EGFR-TKI-resistant lung cancer or metastasis prevention.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冰_完成签到 ,获得积分10
1秒前
winew完成签到 ,获得积分10
3秒前
刘永红发布了新的文献求助10
3秒前
阳光应助jeffemily采纳,获得10
3秒前
4秒前
啊哦完成签到,获得积分10
4秒前
文龙完成签到,获得积分10
4秒前
5秒前
在水一方应助emilizhu采纳,获得10
5秒前
7秒前
意安完成签到,获得积分10
7秒前
DFMDFMDFM发布了新的文献求助80
8秒前
8秒前
9秒前
9秒前
zz完成签到 ,获得积分10
9秒前
10秒前
我是老大应助冰_采纳,获得10
10秒前
gzf完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助50
12秒前
斯文败类应助柏林采纳,获得10
13秒前
超帅妙竹发布了新的文献求助10
13秒前
haeyan发布了新的文献求助10
13秒前
13秒前
14秒前
LALA发布了新的文献求助10
15秒前
碧方完成签到 ,获得积分10
16秒前
单薄夜梅完成签到,获得积分20
16秒前
jiaojinghao关注了科研通微信公众号
16秒前
18秒前
xo80完成签到 ,获得积分10
18秒前
小二郎应助Can采纳,获得30
18秒前
19秒前
威武曼安完成签到,获得积分10
19秒前
紧张的紫文完成签到,获得积分10
20秒前
俊逸成危发布了新的文献求助10
21秒前
21秒前
杨轩关注了科研通微信公众号
21秒前
22秒前
北过完成签到,获得积分10
22秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
LRZ Gitlab附件(3D Matching of TerraSAR-X Derived Ground Control Points to Mobile Mapping Data 附件) 2000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5132497
求助须知:如何正确求助?哪些是违规求助? 4333918
关于积分的说明 13502513
捐赠科研通 4170952
什么是DOI,文献DOI怎么找? 2286755
邀请新用户注册赠送积分活动 1287645
关于科研通互助平台的介绍 1228540